(Q46779685)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Xiao-Jun Huang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Xiang-Yu Zhao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ling-Ling Xu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Xin Qian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

language of work or name

English

0 references

publication date

31 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

838-850

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Novel treatment concepts for graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Th17/Treg ratio in human graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

IL-21 is critical for GVHD in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Analyzing real-time PCR data by the comparative C(T) method

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

The IL-17 differentiation pathway and its role in transplant outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Deciphering the role of Th17 cells in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Bone-marrow transplantation (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Diagnosis and management of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

Interleukin-17–Producing T-Helper Cells as New Potential Player Mediating Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem-Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242816

7 January 2021

Identifiers

DOI

10.1002/EJI.201242816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23280509%20AND%20SRC:MED&resulttype=core&format=json

release_xy6ydly7xvdc3iepib3xghoj2a

21 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xy6ydly7xvdc3iepib3xghoj2a

24 November 2022

mapped directly with Wikidata item

1 reference